Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer.

Scandinavian journal of urology·2026
Same author

Corrigendum.

Scandinavian journal of urology·2026
Same author

Calendar time trends in synchronous metastatic urinary bladder cancer before and after the introduction of immune checkpoint inhibitors: a nation-wide population-based cohort study.

Frontiers in oncology·2025
Same author

Applicability of the European Association of Urology 2021 Prognostic Model for Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort.

European urology open science·2025
Same author

Paradigm shift in the treatment of bladder cancer? The Swedish perspective.

Scandinavian journal of urology·2025
Same author

The Swedish cooperation.

Urologic oncology·2025

Related Experiment Video

Updated: Jun 2, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

Bladder tumours: time for a paradigm shift?

Per-Uno Malmström1

  • 1Department of Surgical Sciences, Urology, Academic Hospital, Uppsala, Sweden. per-uno.malmstrom@surgsci.uu.se

BJU International
|April 27, 2011
PubMed
Summary
This summary is machine-generated.

Bladder cancer outcomes remain poor despite advances in other cancer types. New biological data necessitates re-evaluating current bladder cancer models, definitions, and treatment strategies for improved patient survival.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Jun 2, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Bladder cancer outcomes have not improved significantly compared to other cancers.
  • Muscle-invasive bladder cancer has a high mortality rate, and non-muscle-invasive tumors frequently recur.
  • Current diagnostic and treatment paradigms may be inadequate for addressing bladder cancer's complexities.

Purpose of the Study:

  • To critically review the current bladder cancer model using recent biological data.
  • To propose necessary revisions to bladder cancer classification and terminology.
  • To suggest improvements in clinical endpoints and treatment strategies for bladder cancer.

Main Methods:

  • Literature review and critical analysis of existing bladder cancer data.
  • Evaluation of the impact of the World Health Organization (WHO) classification on bladder cancer diagnosis.
  • Synthesis of new biological insights with current clinical understanding.

Main Results:

  • The current WHO classification's blurring of lines between benign tumors and cancer hinders molecular research.
  • Existing endpoints like recurrence and progression require redefinition for better clinical relevance.
  • Surgery alone for locally advanced bladder cancer is insufficient, necessitating systemic treatment integration.

Conclusions:

  • Reintroducing a clearer distinction between benign tumors and cancer is crucial for advancing bladder cancer research.
  • Revised endpoints are needed to accurately reflect disease behavior and treatment efficacy.
  • A multimodal approach combining surgery with early systemic therapy is essential for managing advanced bladder cancer.